Journal of Clinical Medicine · 2020 · 12 citations · 19 references
MedicineHematologyMolecular GeneticsGenomicsMolecular DiagnosticsMolecular OncologyCancer Molecular DiagnosticsDna SequencingMutation AnalysisNext-generation Sequencing In OncologySequencing-based DiagnosticsVariant DetectionAllele FrequencyAllelic Frequency VariationClinical Genomic DiagnosticsDigital PcrNext-generation Sequencing AssaysNext-generation Sequencing-based DetectionNext-generation Sequencing-based DiagnosisVariant Allele Frequency Analysis
Background: Acute myeloid leukemia is a heterogeneous hematological disease, characterized by karyotypic and molecular alterations. Mutations in IDH2 have a role in diagnosis and as a minimal residue disease marker. Often the variant allele frequency during follow up is less than 20%, which represents the limit of detection of Sanger sequencing. Therefore, the development of sensitive methodologies to identify IDH2 mutations might help to monitor patients’ response to therapy. We compared three different methods to identify and monitor IDH2 mutations in patients’ specimens. Methods: Performances of PNA-PCR clamping, droplet digital PCR and Sanger for IDH2 status identification were evaluated and compared in 96 DNA patients’ specimens. Results: In contrast with Sanger sequencing, our results highlighted the concordance between PNA clamping and digital PCR. Furthermore, PNA-PCR clamping was able to detect more mutated DNA with respect to Sanger sequencing that showed several false negatives independently from the allelic frequency. Conclusions: We found that PNA-PCR clamping and digital PCR identified IDH2 mutations in DNA samples with comparable results in a percentage significantly higher compared to Sanger sequencing. PNA-PCR clamping can be used even in laboratories not equipped for sophisticated analyses, decreasing cost and time for IDH2 characterization.
19
Wei Xu, Hui Yang, Ying Liu et al. · Cancer Cell · 2011 · 2.8K citations · Full text
PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules
Ole Buchardt, Leif Christensen, Carsten Behrens et al. · Nature · 1993 · 2.1K citations
The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury, Kar Kheng Yeoh, Ya‐Min Tian et al. · EMBO Reports · 2011 · 1K citations · Full text